<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03529916</url>
  </required_header>
  <id_info>
    <org_study_id>12841</org_study_id>
    <nct_id>NCT03529916</nct_id>
  </id_info>
  <brief_title>Endothelial Cell Gene Networks of CVD</brief_title>
  <official_title>Endothelial Cell Gene Networks of CVD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to identify relevant signature gene networks of cardiovascular&#xD;
      disease in endothelial cells derived from circulating endothelial progenitor cells of&#xD;
      individuals with established cardiovascular disease (CVD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose to enroll CVD and healthy subjects between 30 and 60 years of age,&#xD;
      matched for age, gender, body mass index, and medication (statin and anti-hypertensive) use.&#xD;
      Circulating endothelial progenitor cells will be isolated from blood and cultured in vitro to&#xD;
      differentiate into endothelial cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No eligible participants were recruited&#xD;
  </why_stopped>
  <start_date type="Actual">May 21, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 23, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gene expression</measure>
    <time_frame>10 weeks</time_frame>
    <description>Gene expression [ identify relevant signature gene networks of cardiovascular disease in endothelial cells]</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>CVD subjects</arm_group_label>
    <description>CVD will be defined as &gt;50% stenosis of one or more coronary arteries as assessed by coronary angiography.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <description>healthy controls defined as not having stenosis of coronary arteries as assessed by coronary angiography.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>isolation of endothelial cells precursors in blood</intervention_name>
    <description>Circulating endothelial precursor cells will be isolated and then cultured in vitro. RNA will be then isolated.</description>
    <arm_group_label>CVD subjects</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood will be obtained and subjected to isolation of circulating endothelial progenitor cells&#xD;
      using pre-specified antibody micro-beads.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Both CVD and healthy subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for CVD subjects::&#xD;
&#xD;
        • &gt;50% stenosis of one or more coronary arteries&#xD;
&#xD;
        Inclusion Criteria for Healthy subjects:&#xD;
&#xD;
        • absence of coronary artery stenosis&#xD;
&#xD;
        Exclusion Criteria for all subjects:&#xD;
&#xD;
          -  type 2 diabetes mellitus&#xD;
&#xD;
          -  chronic kidney disease,&#xD;
&#xD;
          -  other chronic diseases&#xD;
&#xD;
          -  dyslipidemia (fasting plasma LDL-C &gt;160 mg/dL and triglyceride levels &gt;150 mg/dL)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefania Lamon-Fava, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts Medical Center - Cardiovascular Clinic</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tufts University</investigator_affiliation>
    <investigator_full_name>Stefania lamon-Fava</investigator_full_name>
    <investigator_title>Scientist I, Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

